{
    "clinical_study": {
        "@rank": "122957", 
        "brief_summary": {
            "textblock": "To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to\n      identify the minimal effective dose of pentostatin defined as the lowest dose that produces\n      a response in 20% or more of patients while producing treatment failure (defines as death,\n      grade 3/4 toxicity, or progressive disease) in 40% or less of patients."
        }, 
        "brief_title": "Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD", 
        "condition": "Acute Graft Versus Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Patients 6 months of age with grade 2 GVHD that is steroid-refractory\n\n          -  Must be engrafted with ANC 1000/mL, may still be transfusion dependent for platelets\n             and PRBC\n\n          -  Time post stem cell infusion < 100 days\n\n          -  Written informed consent\n\n          -  Must have adequate renal function (creatinine clearance 40 mL/min/1.73 m2\n\n        Exclusion:\n\n          -  Post-transplant lymphoproliferative disease\n\n          -  Uncontrolled infection\n\n          -  Mental illness or other condition preventing full cooperation with the treatment and\n             monitoring requirements of the study\n\n          -  ATG within the previous 14 days\n\n          -  Other immunosuppressive agents (including monoclonal antibodies) when initiated\n             within the previous 7 days."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "April 2, 2002", 
        "id_info": {
            "nct_id": "NCT00032773", 
            "org_study_id": "SGI-NIP-010", 
            "secondary_id": "NIP-010"
        }, 
        "intervention": {
            "intervention_name": "pentostatin for injection", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Pentostatin"
        }, 
        "keyword": [
            "acute graft versus host disease", 
            "aGVHD", 
            "allogeneic hematopoietic stem cell transplantation", 
            "peripheral blood stem cell transplantation", 
            "cord blood transplant", 
            "pentostatin", 
            "Nipent", 
            "deoxycoformycin"
        ], 
        "lastchanged_date": "October 12, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Sequentially Adaptive, Open Label, Dose-finding, Phase I/II Trial of Pentostatin in the Treatment of Steroid-refractory Acute Graft Versus Host Disease (aGvHD)", 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00032773"
        }, 
        "source": "Astex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2005"
    }, 
    "geocoordinates": {
        "MD Anderson Cancer Center": "29.76 -95.369"
    }
}